Case Report: Response to ipilimumab and nivolumab in a patient with adrenocortical carcinoma

Case Report: Response to ipilimumab and nivolumab in a patient with adrenocortical carcinoma

BackgroundAdrenocortical carcinoma (ACC) is a rare malignancy with limited treatment options. The evidence for the use of immunotherapy in ACC has been conflicting, with overall response rates ranging from 6 – 33%.Case presentationWe describe the case of a 32 year old patient who was initially thoug...

Full description

Bibliographic Details
Main Authors: Rebecca Charles, Divine Madhu, Alexander Powles, Adam Boyde, Owen Hughes, Nagappan Kumar, Sing Yu Moorcraft
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-09-01
Series:Frontiers in Oncology
Subjects:
adrenocortical cancer
adrenal cancer
immunotherapy
ipilimumab
nivolumab
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2023.1242560/full

Similar Items

Similar Items